【摘 要】
：
Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer.However, drug resistance has become a major impediment to the successful treatment of ovarian cancer.To date
【机 构】
：
VP of R&D Monarch Life Sciences Proteomics Indiana University USA
【出 处】
：
BIT‘s2nd Annual World Cancer Congess-2009 (2009第二届癌症大会)
论文部分内容阅读
Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer.However, drug resistance has become a major impediment to the successful treatment of ovarian cancer.To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear.In this study, we applied a LC/MS-based, label-free, protein quantification method to examine the global protein expression profiles of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/cisplatin-resistant) and 2008/2008-C 13*5.25 (cisplatin-sensitive/cisplatin-resistant).We identified and quantified over 2000 proteins from these cell lines and 95 proteins showed significant expression changes between sensitive and resistant groups with a false-discovery-rate (FDR) of less than 5%.Bioinformatics analysis suggested several potential pathways that may be involved in cisplatin resistance.Among these potential pathways, a redox regulated pathway involving superoxide dismutase 1 (SOD1) was targeted in order to further explore its involvement in drug resistance.SOD 1 represents a potential biomarker for early evaluation of drug resistance.Inhibition of SOD 1 activity enabled re-sensitization of the cisplatin resistant ovarian cancer cells.This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for potential biomarkers of cisplatin resistance in ovarian cancer.Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.
其他文献
Sphingolipids have long been considered as building blocks of cell architecture, but in the last few years there has been important progress in our understanding of the role of these molecules in cont
Programmed cell death 4 (PDCD4) is classified as a translation regulator and was reported to inhibit the carcinogenesis promoted by the tumor promoter 12-O-tetradecanoilphorbol-13-acetate (TPA), a kno
Many human tumors have activated the protein kinase Akt either by activation of the oncogene PI3Kα or by inactivation of the tumor suppressor PTEN.When activated, Akt phosphorylates and thereby inacti
The BCR-ABL 1 oncogene is the molecular hallmark of chronic myelogenous leukemia (CML), a disease which has been revolutionized by the development of kinase inhibitors that specifically target the onc
Serum amyloid A (SAA) is an acute phase protein whose blood levels are elevated to a 1000-fold in response to various inflammatory stimuli including infection, tissue injury and neoplasia.SAA is the p
Cisbio Bioassays has developed a comprehensive line of HTRF (homogeneous time-resolved fluorescence) reagents for assessing oncology-related targets such kinases, ATPases, ubiquitin and heparanase ass
RUNX3 is a tumor suppressor and belongs to a family of transcription factors RUNX that has been reported to be inactivated in more than 80% of gastric cancers.In this study, we demonstrated that Akt t
Growth factor (GF) signal transduction is now a generally accepted target for antitumor therapy.Various drugs targeting both ligand-binding and tyrosine kinase domains of GF receptors were developed a
Telomerase activation plays a critical role in tumorigenesis.The expression of the human telomerase reverse transcriptase catalytic subunit (hTERT) is well-correlated with telomerase enzymatic activit
The introduction of preoperative radiotherapy (RT) in the treatment of rectal cancer has reduced the frequency of local recurrence and improved patient survival, and RT is now a part of the standard t